Abstract:Background: Vitamin D and folate are influenced by ultraviolet radiation (UVR), and both are implicated in skin carcinogenesis. Polymorphisms in the genes involved in the metabolism of these two compounds may alter the risk of basal cell carcinoma (BCC).

What's already known about this topic?• Action spectra (wavelength dependence) for erythema and the cutaneous formation of vitamin D overlap considerably in the ultraviolet (UV)B region.• Theoretically, sunscreens that inhibit erythema should also inhibit vitamin D synthesis.The study was approved by the Ethics Committee of the Medical University of Ł od z, Poland and done according to the Declaration of Helsinki. All participants (n = 79) gave written informed consent. Most were of Fitzpatrick skin type (FST) II and III. 32 The group demographics and study locations are summarized in Tables 1 and 2. Briefly, three groups of holidaymakers from Ł od z, Poland, spent a week during March

This summary relates to https://doi.Summary 在英国,皮肤癌发病率的增速比其他形式癌症更快。此病中致死性最强的形式为黑色素瘤皮肤癌,现在所影响 的人数比 28 年前增多了128%。已知防晒系数 (SPF) 在按 2 mg /cm 2 外用防晒霜时可以保护皮肤免于日晒 伤。但是,当在假期时,人们通常只外用 0.8 mg / cm 2 防晒霜 此研究旨在确定每天暴露于日光的假期中的通常 防晒霜使用是否会导致诸如日晒伤等皮肤癌风险因素。参与者们在 Tenerife 度过一周,Tenerife 是一个紫外线 指数非常高的地区。22 名参与者在无指导情况下自行使用他们的防晒霜,向 40 名参与者提供 SPF 15 防晒霜 和有效使用的指南(每天三次,2 mg /cm 2 )。发现遵守通常防晒霜使用方式的参与者中日晒伤和其他与皮肤癌 相关风险因素的水平显著高于遵守优化使用指南以达到 SPF 15 的参与者。遵守 SPF 15 防晒霜有效使用指南 的个体在 5 个身体暴露部位没有发生日晒伤。这项研究的结果强调了防晒霜的通常使用在大部分人群中不能 提供充分的日光防护。不仅如此,它还证实日晒伤与皮肤癌的发生风险增高相关。因此,通过教育公众如何正 确使用防晒霜来获得充足的 SPF 可能是防止皮肤癌的一个重要措施。

Introduction: In the last decades the number of skin carcinomas has dramatically increased, which is mainly connected with changes in lifestyle, especially with common use of artificial light sources such as sunbeds. Basal cell carcinoma (BCC) is the most common form of skin cancer in white populations. Basal cell carcinomas are divided into subtypes, depending on their clinical picture and histology. The main groups are nodular (nBCC) and superficial (sBCC) ones. The major recognized risk factors for basal cell carcinoma (BCC) are exposure to chronic and intermittent burning doses of sunlight. Other risk factors leading to the development of the nBCC and sBCC subtypes of BCC are not well established. Material and methods: An analysis of 123 patients with either nBCC or sBCC, living in Lodz, Poland, regarding various intrinsic and environmental parameters was undertaken following the histological diagnosis of BCC. Results: No statistical differences were observed between the BCC subtype and sex, age, hair colour, eye colour, smoking, family history of skin cancer, occupation, or past episodes of sunburn. While sBCCs tended to occur on unexposed body sites in phototype I/II subjects who mainly avoided direct sunlight, nBCCs tended to occur on sun-exposed body sites in phototype III subjects who were frequently in direct sunlight. Conclusions: Thus the development of particular BCC subtypes is partially dependent on phototype and personal sun behaviour.

IntroductionAtopic dermatitis (AD) is a chronic skin inflammatory disease in which Th2-derived cytokines play an essential role. Aim of the study was to assess interleukin 4, 10 and 13 (IL-4, IL-10 and IL-13) serum concentrations in AD patients and to correlate the values with the occurrence of genotypes of selected polymorphisms in genes encoding these cytokines.Material and methodsSeventy-six AD patients (mean age 11.4 years) and 60 healthy controls were enrolled in the study. Blood samples were analyzed for IL-4, IL-10 and IL-13 concentrations with ELISA assay and genotyping for –590C/T IL-4, –1082A/G IL-10 and –1055C/T IL-13 polymorphisms with PCR-RFLP.ResultsThe obtained results revealed statistically higher serum concentration of IL-10 and IL-13 in AD patients when compared to healthy controls (10.30 pg/ml vs. 8.51 pg/ml for IL-10 and 5.67 pg/ml vs. 4.98 pg/ml for IL-13). There were no significant differences between AD patients and controls in regard to IL-4 serum level (5.10 pg/ml vs. 7.1 pg/ml). Analyzing the association between level of the examined cytokines and genotype polymorphisms –590 C/T for the IL-4 gene, –1082 A/G for the IL-10 gene and –1055 C/T for the IL-13 gene, we found a statistically higher IL-10 serum level among carriers of the G allele in the –1082 G/A IL-10 polymorphism both in AD and control groups. We did not find any significant differences between serum level of IL-4 and IL-13 in regard to genotype occurrence in examined polymorphisms: –590 C/T for the IL-4 gene and –1055 C/T for the IL-13 gene. ConclusionsThe obtained results confirm the genetic background of IL-10 synthesis in the Polish population.

Careful consideration must be given to the health outcomes of childhood solar exposure, and a much better understanding of the risk-benefit relationships of such exposure is required. Rigorous photoprotection is necessary for children, even in Northern Europe.

No abstract

Skin mucinosis is a rare skin disease which clinically manifests as firm papules and waxy nodules. We report a case of a 66-year-old female psoriatic patient who developed skin mucinosis during biological therapy. Because of a previous lack of response to the local and conventional systemic treatment of psoriasis, the patient received biological therapy (infliximab from June 2008 to May 2009 – initial clinical improvement and loss of treatment effectiveness in the 36th week of the therapy; adalimumab from June 2009 to January 2010 – lack effectiveness; ustekinumab from March 2012 to the present). Throughout 2 months we observed a manifestation of the skin mucinosis as well-demarcated, yellow and brown, papulo-nodular lesions of 5–10 mm in diameter, localized on the back. Histopathological examination with alcian blue staining demonstrated mucin deposits in the dermis. On the basis of clinical and histopathological findings, the diagnosis of cutaneous focal mucinosis was established. We present the case because of the extremely rare occurrence of the disease. Scarce literature and data suggest that there is an association between focal mucinosis and thyroid dysfunction, as well as possible adverse effects of biological therapy with TNF-α antagonists.